Citicoline and alpha-GPC are not interchangeable.

Evidence at a glance

Comparisons hub · What citicoline is · Side effects · Dosage in studies

A closer reading

Why these two compounds get compared so often

Citicoline (CDP-choline) and alpha-GPC sit next to each other on supplement shelves and in the same online conversations. Both are described as choline sources, and both show up in products marketed for focus, memory, and healthy aging. From the outside, that can make them look like two flavors of the same thing.

They are not. They are different molecules with different chemistry, different histories of study, and different evidence bases. This page explains what the citicoline register actually supports when these two names get placed side by side, and, just as importantly, what it does not.

The starting point is a honest one: this register does not contain a head-to-head trial that compares citicoline against alpha-GPC for memory, stroke recovery, or attention. No winner can be declared from the evidence tracked here. Anyone who tells you one is clearly "better" than the other is making a claim that goes beyond what direct comparison studies show.

The chemistry is genuinely different

The two compounds share a connection to choline, and that is where the similarity largely ends.

Citicoline is CDP-choline, cytidine diphosphate-choline. When the body processes it, it yields choline and cytidine. The cytidine half matters because cytidine is a building block used elsewhere in the body, including in pathways tied to cell membrane components. Evidence suggests citicoline supports membrane phospholipid synthesis, though the stronger neuroprotection claims attached to that mechanism remain preclinical, shown in laboratory and animal work, not confirmed as clinical outcomes in people.

Alpha-GPC is a different choline-containing compound. It delivers choline through its own structure and its own pathway. That is a real chemical distinction, not a marketing one.

Here is the calibration that matters: the structural difference between these molecules is a fact of chemistry. It is not, by itself, proof that one works better than the other for anything. A molecule that does more things on paper is not automatically a molecule that helps more people in practice. Only trials can answer that question, and the head-to-head trial does not exist in this register.

What citicoline's own evidence looks like, including the negative results

Because citicoline's trial record is part of this comparison, it should be presented in full, not just the flattering parts.

Acute stroke. The largest trial of citicoline in acute stroke, ICTUS, published in The Lancet in 2012 by Dávalos and colleagues with about 2,300 participants, found no improvement in 90-day recovery versus placebo. Earlier meta-analyses of smaller stroke trials had suggested benefit, but that signal was not confirmed by the largest trial. This is one of the most important results in the entire citicoline literature, and it is a negative one.

Traumatic brain injury. The COBRIT trial, published in JAMA in 2012 by Zafonte and colleagues, found that citicoline did not improve functional or cognitive outcomes versus placebo. Again: a large, careful trial, and a negative result.

Chronic cerebrovascular cognitive decline. A Cochrane review by Fioravanti and Yanagi found modest short-term benefit on memory and behaviour, but the underlying trials were short and of low quality. That is a weaker grade of evidence, and it should be read that way.

Mild vascular cognitive impairment. The IDEALE study, an observational study by Cotroneo, found an association between citicoline use and stable scores compared with decline in an untreated group. Observational designs cannot prove cause and effect.

Attention in healthy people. Two small trials by McGlade and colleagues, both funded by the maker of Cognizin, found better attention-test scores in women at 250 and 500 mg, and gains in attention and psychomotor speed in adolescent males. These were small and industry funded, worth noting, not definitive.

The pattern across this record is worth stating plainly: the largest and best-controlled citicoline trials in stroke and brain injury were negative, while the positive signals come from smaller, shorter, or lower-quality studies. None of this evidence transfers to alpha-GPC, and none of alpha-GPC's evidence is rewritten here as if it belonged to citicoline.

A safety note that belongs on any page touching cognition: sudden facial droop, arm weakness, or speech difficulty can be a stroke. Call 911 immediately. No supplement is a response to those symptoms.

Why negative citicoline trials say nothing about alpha-GPC, and vice versa

This point trips people up, so it deserves its own section.

When ICTUS and COBRIT came back negative for citicoline, those results applied to citicoline. They did not quietly downgrade every choline-related compound. And if alpha-GPC has its own trials, positive or negative, those results belong to alpha-GPC. Compounds are not interchangeable in chemistry, and their trial results are not interchangeable either.

This cuts in both directions:

• You cannot cite citicoline's stroke trials as evidence against alpha-GPC.
• You cannot cite any alpha-GPC finding as evidence for citicoline.
• You cannot average the two together into a single "choline supplement" verdict.

Labels and articles that treat these compounds as swaps, implying that evidence for one automatically covers the other, are ahead of the evidence this site is willing to state. When you read a claim about either compound, the first question to ask is: which molecule was actually studied, in which people, and with what result?

What a real head-to-head answer would require

To say one compound works better than the other for a specific outcome, you would need trials that randomize people to citicoline or to alpha-GPC, measure the same outcomes the same way, and follow participants long enough to matter. This register does not contain such a trial for memory, stroke, or attention.

Without that design, comparisons rest on indirect evidence, separate trials run in different populations, at different doses, with different measures. Indirect comparisons are fragile. A compound with more trials is not necessarily a more effective compound; it may simply be a more studied one. A compound with a positive small trial and a compound with a negative large trial cannot be ranked against each other from those two facts alone.

This is why the honest answer to "which works better?" is that this register does not show a head-to-head winner. That is not a dodge. It is what the evidence supports.

Choosing by the question you actually have

A more useful way to think about these compounds is to start with your actual question rather than with a product comparison.

If your question is about citicoline specifically, what it is, what its trials found, what doses were used in studies, and what side effects were reported, the rest of this site covers that in detail. Citicoline evidence, condition by condition walks through the full register, including the negative trials. Citicoline doses used in studies and citicoline side effects cover the practical safety picture: citicoline was generally well tolerated at 250 to 2,000 mg per day in trials, with mild GI upset, headache, and insomnia among the reported effects. Pregnancy and breastfeeding data are lacking.

If your question is about alpha-GPC's own evidence, that literature lives outside this register and should be evaluated on its own terms, with the same skepticism applied to citicoline here: Who was studied? How large was the trial? Was it industry funded? Were the biggest trials positive or negative?

If your question is whether to take both together, this site does not recommend stacks. Combining products multiplies unknowns rather than canceling them. Ask your doctor before combining supplements, and bring up everything you take, because interactions matter. As one example within this register, citicoline may enhance levodopa's effects, which is why people with Parkinson's disease should involve their neurologist before using it.

Whatever your question, citicoline is sold in the United States as a dietary supplement, not an FDA-approved drug. It is not a treatment, cure, or prevention for stroke, dementia, glaucoma, ADHD, or brain injury, and neither compound should be used in place of medical care.

The short version

Citicoline (CDP-choline) and alpha-GPC are different compounds that happen to share a choline connection and a marketing neighborhood. The chemistry differs in a real way, but chemistry alone does not crown a winner. Citicoline's own trial record includes large negative trials in stroke and brain injury alongside smaller positive signals elsewhere, and none of that record can be borrowed by, or held against, alpha-GPC. No head-to-head trial in this register settles the comparison.

Choose by the question you actually have, and answer it with your doctor. For citicoline's side of the story, start with the evidence hub, the safety overview, and how to read a citicoline label, which stays on citicoline, not a catalog of every choline product.